China Earnings Roundup: China Medicine, China Biologic, 3SBio Post Strong Growth
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Guangdong-based China Medicine reported a 60 percent rise in net income to $3.2 million in the third quarter. That growth was driven by an almost 400 percent sales increase in second- and third-tier cities as a result of the Chinese government's $124 billion healthcare reforms (PharmAsia News, April 8, 2009)
You may also be interested in...
China Issues Three-year Healthcare Reform Plan To Invest RMB 850 Billion
SHANGHAI - China issued its long-awaited three-year plan for its healthcare reform, and unveiled how the country will allocate RMB 850 billion ($124 billion) in the next three years
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).